| __timestamp | Galapagos NV | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 9079000 | 91733000 |
| Thursday, January 1, 2015 | 20309000 | 87644000 |
| Friday, January 1, 2016 | 16945000 | 92365000 |
| Sunday, January 1, 2017 | 20559000 | 85656000 |
| Monday, January 1, 2018 | 29641000 | 88196000 |
| Tuesday, January 1, 2019 | 88258000 | 89971000 |
| Wednesday, January 1, 2020 | 162170000 | 93413000 |
| Friday, January 1, 2021 | 167218000 | 91355000 |
| Saturday, January 1, 2022 | 239528000 | 113676000 |
| Sunday, January 1, 2023 | 94252000 | 198366000 |
| Monday, January 1, 2024 | 218935000 |
Data in motion
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Taro Pharmaceutical Industries Ltd. and Galapagos NV, two prominent players, have shown contrasting trends in their SG&A expenses from 2014 to 2023. Taro consistently maintained a more stable SG&A cost, averaging around 113 million annually, with a notable peak in 2024. In contrast, Galapagos NV experienced a dramatic rise, peaking in 2022 with a 239% increase from 2014, before a sharp decline in 2023. This fluctuation suggests Galapagos NV's aggressive expansion strategies, while Taro's steadiness reflects a more conservative approach. Understanding these trends offers valuable insights into each company's operational strategies and financial health. As the industry evolves, monitoring these expenses will be key to sustaining growth and competitiveness.
AbbVie Inc. or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Biogen Inc. and Taro Pharmaceutical Industries Ltd.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Galapagos NV
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Taro Pharmaceutical Industries Ltd.
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Taro Pharmaceutical Industries Ltd.
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Galapagos NV
SG&A Efficiency Analysis: Comparing Opthea Limited and Galapagos NV
Selling, General, and Administrative Costs: Verona Pharma plc vs Galapagos NV
Operational Costs Compared: SG&A Analysis of Apellis Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.
Who Optimizes SG&A Costs Better? Arrowhead Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.
SG&A Efficiency Analysis: Comparing ImmunityBio, Inc. and Taro Pharmaceutical Industries Ltd.
Soleno Therapeutics, Inc. or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?